Hospital Medicine

The completion of this study concluded the planned clinical development program for nasal nalmefene and the company expects to file a New Drug Application in the second half of 2022.

Investigators suggested that the practice of insurance redlining could be manifesting itself via ACA health exchanges.

This episode features a conversation with Dr. Amelle Shillington and Jacob and Ashley Wiley after Shillington diagnosed the extremely rare genetic disease that's afflicted Aislynn Wiley, and only 69 other documented cases worldwide.

Antibiotic and proton pump inhibitor use was also associated with an increased risk of C difficile infection.

Nancy Holekamp, MD discusses the substantial emotional burden and impact on independence of GA reported in the Geographic Atrophy Insights Survey.

ANCA-associated vasculitis may present like sinusitis, but it typically affects multiple organ systems.

Emergency medicine specialist urges hospitals to add methylnaltrexone to the hospital formulary after promising research shows the treatment's success with opioid-induced constipation.

Rural patients identifying as Black had a more than 10% absolute increased risk of major leg amputation or death compared with the overall cohort with diabetic foot ulcers.

The 2022 State of the Air report from the American Lung Association highlights growing disparities in coastal-based ozone and particle pollution, amid wildfires and shifts in regulatory policies.

The company reported interim results at a meeting this week showing multiple formulations were tolerable and safe. Next comes a phase 2 trial.

A new method of opioid disposal was proposed by the FDA in an attempt to mitigate unauthorized access to opioids and lessen risk of addiction.

About 1 in 5 recent novel drug approvals were based on data extrapolated to a broader patient population or in regard to a concomitant drug use, including the controversial aducanumab indication from 2021.

Bianca K. Frogner, PhD, discusses the prevalence of burnout and job dissatisfaction observed across various health care worker roles and settings.

New research shows diarrhea did not increase overall mortality for hospitalized patients.

The most common comorbidities for adults were hypertension, hyperlipidemia, and diabetes.

C Difficile infections decreased in VA healthcare facilities during the COVID-19 pandemic.

Data show the life expectancy of Hispanic and non-Hispanic Black Americans decreased by more than 3 years during the pandemic.

A study highlights methods to define hydroxyurea exposure as means of understanding hematologic benefit derived from the first-line drug for children.

The protocol appeared safe, with no associated increases in the incidence of hypoglycemic events during hospitalization or 30-day mortality.

A survey analysis suggests the worst of turnover in the workforce occurred in 2020, but focus is needed to recover health care workers from specific fields.

National registry data suggest management and outcomes of ST-elevation myocardial infarction are returning to pre-pandemic levels, though vaccinated patients have fared better in mortality.

Data from PROMPT-HF show clinicians are more likely to add 1 of 4 topline drug classes to a patient's HFrEF regimen when alerted on the opportunity.

Mikhail Kosiborod, MD, discusses EMPULSE findings supporting hospital-stage treatment with the SGLT-2—regardless of patients' diabetes status.

Dr. Rafael Pérez-Figueroa talks about how the pandemic has exacerbated racial inequities on multiple levels saying that people of color have been overrepresented in jobs with high exposure to COVID-19, leading to disproportionate infections and death.

Deepak L. Bhatt, MD, MPH, reviews the latest phase 2b trial data supporting the fast-acting monoclonal antibody infusion for bleeding risk reversal.

VOYAGER PAD subgroup analyses showed the anticoagulant reduced likelihood of hospitalization without increasing bleeding risk in patients with CKD.

Investigators believe the novel monoclonal antibody may be a suitable agent in patients with major bleeding risk or those undergoing surgery.

The NaV1.8 inhibitor VX-548 shows promising potential as a non-opioid acute pain treatment.

Team-based care shows the reduction of multiple risk factors, attainment of multiple treatment targets, and empowerment among high-risk patients with DKD.